Pyxis Oncology Inc (NASDAQ: PYXS) is a clinical-stage biotechnology company focused on developing next-generation cancer therapies. By harnessing the power of antibody-drug conjugates (ADCs) and immuno-oncology approaches, the company aims to create targeted treatments that improve outcomes for cancer patients. With a commitment to scientific innovation and precision medicine, Pyxis Oncology is advancing a pipeline of novel therapies designed to enhance the effectiveness and safety of cancer treatments. As it progresses through clinical trials, the company remains dedicated to transforming oncology care with cutting-edge biopharmaceutical solutions.
Latest shares articles
Barrick Gold forecast: Third-party price target
Discover the Barrick Gold (GOLD) price predictions for 2025 and beyond, with analyst price targets and more on Capital.com
15:41, 8 May 2025
US stocks hold ground despite Powell’s stagflation warning
US equities continue to attract buying interest backed by improved market sentiment despite Powell's warning about stagflation
11:29, 8 May 2025
Alibaba price forecast: Third-party price targets
On 26 March 2025, the price of Alibaba (BABA) shares had increased by approximately 57.49% year-to-date (YTD) and 89.75% year on year.
10:53, 30 April 2025
Amazon Q1 Preview: AI Ambitions Under Scrutiny Amid Trade Policy Headwinds and Margin Pressures
Amazon (AMZN) is set to report its Q1 2025 results after the close on May 1, with investors closely watching how the e-commerce and cloud giant is navigating a more challenging macroeconomic environment.
10:15, 30 April 2025
Ratings and Reviews
Ratings and Reviews
